Drug Type Autologous CAR-T |
Synonyms Anti-BCMA CAR-T cell therapy - Juventas Cell Therapy, HY 015, HY-015 |
Target |
Action inhibitors |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | China | 30 Jan 2022 |